Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP, Stahl M, Zeidan AM. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Leukemia & Lymphoma 2019, 60: 1354-1369. PMID: 30652518, DOI: 10.1080/10428194.2018.1546854.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAML patientsPivotal clinical trial dataOverall survival rateAcute myeloid leukemiaClinical trial dataMechanism of actionIntensive chemotherapyRefractory AMLOlder patientsAML treatmentCD33 antibodyPreclinical dataMyeloid leukemiaClinical developmentTherapeutic revolutionUS FoodDrug AdministrationSurvival rateAdvanced stagePatientsFDA approvalTrial dataPromising agentNovel therapeuticsNew drugs